Oxford Nanopore Technologies (ONT) Competitors

Oxford Nanopore Technologies logo
GBX 188.70 -10.80 (-5.41%)
As of 12:40 PM Eastern

ONT vs. OBI, ABC, OXB, SLN, and HZD

Should you buy Oxford Nanopore Technologies stock or one of its competitors? Oxford Nanopore Technologies's main competitors and comparable companies include Ondine Biomedical (OBI), Abcam (ABC), Oxford Biomedica (OXB), Silence Therapeutics (SLN), and Horizon Discovery Group plc (HZD.L) (HZD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Oxford Nanopore Technologies compare to Ondine Biomedical?

Ondine Biomedical (LON:OBI) and Oxford Nanopore Technologies (LON:ONT) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Oxford Nanopore Technologies has a consensus price target of GBX 213.60, suggesting a potential upside of 5.85%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ondine Biomedical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Oxford Nanopore Technologies has a net margin of -51.66% compared to Ondine Biomedical's net margin of -1,150.26%. Oxford Nanopore Technologies' return on equity of -27.36% beat Ondine Biomedical's return on equity.

Company Net Margins Return on Equity Return on Assets
Ondine Biomedical-1,150.26% -24,731.60% -159.71%
Oxford Nanopore Technologies -51.66%-27.36%-14.42%

Ondine Biomedical has a beta of 0.298, indicating that its share price is 70% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.871, indicating that its share price is 13% less volatile than the broader market.

32.8% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 19.3% of Oxford Nanopore Technologies shares are owned by institutional investors. 29.0% of Ondine Biomedical shares are owned by company insiders. Comparatively, 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ondine Biomedical has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ondine BiomedicalC$2.88M1,987.33-C$424.66K-C$6.00N/A
Oxford Nanopore Technologies£235M8.42-£175.21M-£12.50N/A

In the previous week, Oxford Nanopore Technologies had 6 more articles in the media than Ondine Biomedical. MarketBeat recorded 8 mentions for Oxford Nanopore Technologies and 2 mentions for Ondine Biomedical. Oxford Nanopore Technologies' average media sentiment score of 0.74 beat Ondine Biomedical's score of 0.74 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ondine Biomedical
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oxford Nanopore Technologies
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Oxford Nanopore Technologies beats Ondine Biomedical on 10 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Abcam?

Abcam (LON:ABC) and Oxford Nanopore Technologies (LON:ONT) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

In the previous week, Oxford Nanopore Technologies had 8 more articles in the media than Abcam. MarketBeat recorded 8 mentions for Oxford Nanopore Technologies and 0 mentions for Abcam. Oxford Nanopore Technologies' average media sentiment score of 0.74 beat Abcam's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company Overall Sentiment
Abcam Neutral
Oxford Nanopore Technologies Positive

Oxford Nanopore Technologies has a consensus price target of GBX 213.60, suggesting a potential upside of 5.85%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Abcam.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abcam
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83

Abcam has higher revenue and earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abcam£350.40M0.00N/A£0.06N/A
Oxford Nanopore Technologies£235M8.42-£175.21M-£12.50N/A

19.3% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Abcam has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -51.66%. Abcam's return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
AbcamN/A N/A N/A
Oxford Nanopore Technologies -51.66%-27.36%-14.42%

Summary

Oxford Nanopore Technologies beats Abcam on 7 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Oxford Biomedica?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Oxford Biomedica has a net margin of -23.23% compared to Oxford Nanopore Technologies' net margin of -51.66%. Oxford Nanopore Technologies' return on equity of -27.36% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-51.66% -27.36% -14.42%
Oxford Biomedica -23.23%-54.51%-12.67%

19.3% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 43.3% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Oxford Nanopore Technologies had 6 more articles in the media than Oxford Biomedica. MarketBeat recorded 8 mentions for Oxford Nanopore Technologies and 2 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 0.74 beat Oxford Biomedica's score of -0.81 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oxford Nanopore Technologies
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oxford Biomedica
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Negative

Oxford Nanopore Technologies has a beta of 0.871, meaning that its share price is 13% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.106, meaning that its share price is 11% more volatile than the broader market.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M8.42-£175.21M-£12.50N/A
Oxford Biomedica£175.36M3.55-£143.51M-£31.96N/A

Oxford Nanopore Technologies currently has a consensus price target of GBX 213.60, suggesting a potential upside of 5.85%. Oxford Biomedica has a consensus price target of GBX 818, suggesting a potential upside of 59.45%. Given Oxford Biomedica's higher probable upside, analysts plainly believe Oxford Biomedica is more favorable than Oxford Nanopore Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75

Summary

Oxford Nanopore Technologies and Oxford Biomedica tied by winning 8 of the 16 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Silence Therapeutics?

Oxford Nanopore Technologies (LON:ONT) and Silence Therapeutics (LON:SLN) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Silence Therapeutics has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -51.66%. Silence Therapeutics' return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-51.66% -27.36% -14.42%
Silence Therapeutics N/A N/A N/A

19.3% of Oxford Nanopore Technologies shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Oxford Nanopore Technologies had 8 more articles in the media than Silence Therapeutics. MarketBeat recorded 8 mentions for Oxford Nanopore Technologies and 0 mentions for Silence Therapeutics. Oxford Nanopore Technologies' average media sentiment score of 0.74 beat Silence Therapeutics' score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Oxford Nanopore Technologies Positive
Silence Therapeutics Neutral

Oxford Nanopore Technologies currently has a consensus target price of GBX 213.60, indicating a potential upside of 5.85%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, equities analysts plainly believe Oxford Nanopore Technologies is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Silence Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Silence Therapeutics has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M8.42-£175.21M-£12.50N/A
Silence Therapeutics£11.35M0.00N/A-£48.60N/A

Summary

Oxford Nanopore Technologies beats Silence Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Oxford Nanopore Technologies compare to Horizon Discovery Group plc (HZD.L)?

Oxford Nanopore Technologies (LON:ONT) and Horizon Discovery Group plc (HZD.L) (LON:HZD) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Oxford Nanopore Technologies currently has a consensus price target of GBX 213.60, suggesting a potential upside of 5.85%. Given Oxford Nanopore Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Horizon Discovery Group plc (HZD.L).

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Horizon Discovery Group plc (HZD.L)
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

19.3% of Oxford Nanopore Technologies shares are owned by institutional investors. 2.5% of Oxford Nanopore Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Horizon Discovery Group plc (HZD.L) has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Horizon Discovery Group plc (HZD.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£235M8.42-£175.21M-£12.50N/A
Horizon Discovery Group plc (HZD.L)£54.63M0.00N/A-£5.50N/A

Horizon Discovery Group plc (HZD.L) has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -51.66%. Horizon Discovery Group plc (HZD.L)'s return on equity of 0.00% beat Oxford Nanopore Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-51.66% -27.36% -14.42%
Horizon Discovery Group plc (HZD.L) N/A N/A N/A

In the previous week, Oxford Nanopore Technologies had 8 more articles in the media than Horizon Discovery Group plc (HZD.L). MarketBeat recorded 8 mentions for Oxford Nanopore Technologies and 0 mentions for Horizon Discovery Group plc (HZD.L). Oxford Nanopore Technologies' average media sentiment score of 0.74 beat Horizon Discovery Group plc (HZD.L)'s score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Oxford Nanopore Technologies Positive
Horizon Discovery Group plc (HZD.L) Neutral

Summary

Oxford Nanopore Technologies beats Horizon Discovery Group plc (HZD.L) on 9 of the 13 factors compared between the two stocks.

Get Oxford Nanopore Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ONT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ONT vs. The Competition

MetricOxford Nanopore TechnologiesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£1.85B£3.94B£7.46B£2.68B
Dividend YieldN/A3.64%2.48%5.11%
P/E Ratio-15.1023.6032.5322.78
Price / Sales7.8815.638.104.91
Price / Cash4.0422.6520.7220.23
Price / Book2.814.144.322.40
Net Income-£175.21M-£24.03M£3.51B£5.88B
7 Day Performance-5.18%-9.19%-7.64%-3.52%
1 Month Performance-7.32%-13.05%-10.10%-4.94%
1 Year Performance53.17%-5.90%-2.55%4.49%

Oxford Nanopore Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ONT
Oxford Nanopore Technologies
2.2247 of 5 stars
GBX 188.70
-5.4%
GBX 213.60
+13.2%
+63.8%£1.85B£235MN/A1,314
OBI
Ondine Biomedical
N/AC$9.30
-0.5%
N/A-23.1%C$6.15BC$2.88MN/AN/A
ABC
Abcam
N/AN/AN/AN/A£2.81B£350.40M20,433.331,650
OXB
Oxford Biomedica
3.1792 of 5 stars
GBX 549
flat
GBX 818
+49.0%
-13.3%£666.81M£175.36MN/A891
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35MN/A100

Related Companies and Tools


This page (LON:ONT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners